

## COUN 525 Syllabus Psychopharmacology for Counselors

### Course Description

This course is designed to introduce students to the biochemical basis of behavior and a general knowledge of the main effects and side effects of the major classes of psychotropic drugs. Neurobiology will be described in a clear and understandable language in order to help the student with mastery of concepts in the field of psychopharmacology. A historical overview of medicinal approaches, drugs, and prominent healing traditions will initiate the course. A close relationship between the use of a particular class of drugs, the DSM-5 classification, and relevant case studies will be interwoven in this course in order to develop a comprehensive and meaningful image of the client. Essential principles of interpersonal neuroscience will be presented. Integration of prior courses in counseling with new, evolving knowledge in psychopharmacology will be a significant aspect of learning. Classroom instruction will be utilized to determine appropriate referrals for psychiatric evaluation and working with other mental health professionals in providing effective treatment. **Prior exposure and understanding of the DSM-5, case conceptualization and relevant client experience will be expected.** DSM-5 classification will be discussed relative to psychotropic medications.

### Course Objectives

1. To introduce the concept of psychotropic medication as relevant, therapeutic and ethical co-partnering with mainstream counseling and psychotherapy.
2. To provide relevant historical background to the understanding of human experience, psychiatric diagnosis, and the development of the psychotropic drug industry.
3. To present basic neurobiology and its relevance to effective psychopharmacological intervention.
4. Exposure to neuroanatomy of the brain through video brain dissection
5. Examine the pharmacological effect of different drug classes on behavioral, cognitive, and central nervous system operations.
6. Examine the use of clinical diagnosis on the DSM-5 in the determination of pharmacological prescriptions.
7. Examine the application of drugs to the prevention and treatment of specific psychopathological dysfunctions.
8. Understand how factors such as ethnicity/culture, gender, age, sexual orientation, disability, religion/spirituality, and socioeconomic status may impact clinical diagnosis and treatment.
9. Understand the use of drugs in psychopharmacological research.
10. Understand the role of herbal treatments, vitamins and hallucinogens on human experience.
11. Become informed about how to collaborate with medical staff regarding psychotropic medication
12. Understand appropriate ethical guidelines to effective management of psychopharmacological care.

## **Pre-Requisites**

Classified standing and successful completion of COUN 522A or 522B. **Due to required knowledge base, COUN 522A or 522B cannot be taken concurrently with COUN 525.**

## **Student Learning Outcome Language**

As you know, the Counseling department tracks aspects of student learning (known as Student Learning Objectives or SLOs) and Dispositions (Professionalism and Fitness for the Profession) in numerous classes as part of the CACREP accreditation requirements. This helps as a source of feedback on our teaching and lets us know how students are doing on average and individually. In some classes, the SLO's are assessed in the form of a rubric and in other classes it is simply a score from a paper or exam. There is nothing you need to do, but be aware that the information will be used to track and evaluate your progress in the program and will be part of your student record. Please see detailed information in your Student Handbook, as well as the form for Dispositions (which can be used at any time, but is always assessed in Coun 511, 530, and 584). There are at least three times when a student's individual progress is formally examined by the faculty: (1) after they have completed their first semester; (2) at advancement to practicum (the semester prior to starting practicum); and (3) at advancement to research project (the semester prior to Final Project). At these points in time, all the assessment information (including any of the SLO assessments conducted, as well as information from advisement, course grades, and professor input) will be examined. The spirit of this is to make sure that you are on track, and if you are not, then our goal is to offer support and guidance so that you can get back on track. If there are serious concerns, this may involve a remediation process or, in rare cases, dismissal from the program. All of this information is outlined in your Student Handbook

## **Calendar**

### **Course Orientation: Introduction and Learning Expectations**

#### Week 1

- Overview of syllabus
- Rationale for MFTs to study psychopharmacology
- Introduction to the integration of psychology, counseling, and neuroscience
- Basic Premises for Psychotropic Medication Use
- Video: Brain Anatomy for Health Professionals- Normal Unfixed Brain (6:19 minutes)

#### *Read:*

Torrey E.F. (2019). *Surviving Schizophrenia: A Family Manual*. New York: Harper [For 02/07/22]

#### Articles:

Ingersoll, R. E. (2000). Teaching a psychopharmacology course to counselors: Justification, structure, and methods. *Counselor Education & Supervision*, 40, 58-68.

Kaut, K.P. (2007). The Mental Health Practitioner and Psychopharmacology. *Journal of Mental Health Counseling*, 29, 204-225.

Muse, M., & McGrath, R. (2010). Training comparison among three professions prescribing psychoactive medications: Psychiatric nurse practitioners, physicians, and pharmacologically trained psychologists. *Journal of Clinical Psychology*, 66, 96-103.

Springer, P. R., & Harris, S.M. (2010). Attitudes and Beliefs of Marriage and Family Therapists Regarding Psychotropic Drugs and Therapy. *Journal of Marital and Family Therapy*, 36, 361-375.

## **Basic Neurobiology**

### Week 2

- Fundamentals of the neuron
- Electrical & Chemical Transmission
- Arborization, Neurogenesis & Neuroplasticity
- Blood Brain Barrier
- Types of Neurotransmitters

### **Note: QUIZ #1 (Surviving Schizophrenia)**

#### *Read:*

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 1 & 2

Preston, J. D. O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of Clinical Psychopharmacology for Therapists*, Chapter 3.

*Youtube Video: History of Psychiatry, 19<sup>th</sup> Century*

#### Articles:

Chiesa, A. (2009). Zen meditation: An Integration of Current Evidence. *The Journal of Alternative and Complementary Medicine*, 15, 585-592.

Stahl, S. (2012). Psychotherapy as an epigenetic 'drug': Psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs. *Journal of Clinical Pharmacy and Therapeutics*, 37(3), 249-253.

Moncrieff, Joanna, & Cohen, David. (2009). How do psychiatric drugs work? *British Medical Journal (Clinical Research Ed.)*, 338, B1963.

## History on the Discovery of Psychotropic Medication

### Week 3

- Values, beliefs and behavior toward mental illness through history
- Influences of physical sciences on the understanding of mental well being
- Coal industry and early formation of pharmaceutical companies
- Emphasis on allopathic medicine
- Contributions of psychiatric advocates and evolving treatments
- Evolution of psychiatric nomenclature and the DSM

#### Read:

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapters 1 & 2.

#### Articles:

Cattaneo, L. & Rissolatti G. (2009). The Mirror Neuron System. *Archives of Neurology*, 66, 557-560.

Fischer, B. A. (2012). A review of American psychiatry through its diagnoses: The history and development of the Diagnostic and Statistical Manual of Mental Disorders. *The Journal of Nervous and Mental Disease*, 200, 1022-1030.

King, J.H. & Anderson, S.M. (2004). Therapeutic implications of psychopharmacology: Current trends and Ethical Issues. *Journal of Counseling and Development*, 82, 329-336.

Moncrieff, J. (2009). The pharmaceutical industry and the construction of psychiatric diagnoses. *Journal of Ethics in Mental Health*, 4, 1-4.

Pallagrosi, M., & Fonzi, L. (2018). On the concept of Praecox feeling. *Psychopathology*, 51, 353-361.

## Basic Neurophysiology and Brain Anatomy

### Week 4

- Organization of the brain
- Brain and spinal cord description
- Brain site location of neurotransmitters
- Exploration of brain structure
- Changes in adolescent brain

#### Pharmacodynamics and Pharmacokinetics

- Drug administration
- Drug absorption, distribution, and metabolism

- Basic pharmacodynamic and pharmacokinetic principles
- Prescription and pharmacy terms
- Exploration of brain structure
- Change in Adolescent Brain

**Note: Reflection Paper (History of Psychopharmacology)**

*Read:*

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 3

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapters 4-5.

**Neuroanatomy Videos:**

- Introduction:  
Neuroanatomy
- The Cerebellum
- Basil Ganglia
  
- Hypothalamus
- Central Localization
- Limbic System

Caffrey, A.R. & Borrelli, E.P. (2021). *The Art and Science of drug titration. Pub Med, 1-27*

Rivas-Vasquez, R.A. (2001). Understanding Drug Interactions. *Professional Psychology: Research and Practice, 32, 543-547.*

**Articles:**

Kindsuatter A. & Geroski A. (2014). The Impact of Early Life Stress on The Neurodevelopment of the stress response system. *Journal of Counseling & Development, 92, 472-480.*

Wzsola, B. A., Newell, K. M., & Sprague, R. L. (2001). Risk factors for tardive dyskinesia in a large population of youths and adults. *Experimental and Clinical Psychopharmacology, 9, 285-296.*

**Basic Neuroscience Examination**

Week 5

**Social and Cultural Perspectives**

- Sex and gender differences
- Cultural and ethnic differences
- Ethno pharmacology
- Brand-name and generic medications
- Treatment considerations

**Read:**

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition.* Boston, MA: Cengage Learning. Chapter 4

**Articles:**

Coid, J., Ullrich, S., Keers, R., Bebbington, P., Destavola, B., et al. (2013). Gang membership, violence, and psychiatric morbidity. *The American Journal of Psychiatry, 170, 985-993.*

Canino, G., & Alegría, M. (2008). Psychiatric diagnosis – is it universal or relative to culture?. *Journal of Child Psychology and Psychiatry, 49(3), 237-250.*

Desmarais, J., Beauclair, L. , & Margolese, H. (2011). Switching from brand-name to generic psychotropic medications: A literature review. *CNS Neuroscience & Therapeutics, 17, 750-760.*

Diaz, E., Woods, S., & Rosenheck, W. (2005). Effects of Ethnicity on Psychotropic Medications Adherence. *Community Mental Health Journal, 41, 521-537.*

- Flaskerud, J. H. (2000). Ethnicity, culture, and neuropsychiatry. *Issues in Mental Health Nursing, 21*, 5-29.
- Jacobsen, F.M. (1995). Can psychotropic medications change ethnoculturally determined behavior? *Cultural Diversity and Mental Health, 1*, 67-72.
- Margolese, H.C., Wolf, Y., Desmarais, J.E., and Beauclair, Linda. (2010). Loss of Response After Switching from Brand Name to Generic Formulations: Three Cases and a Discussion of Key Clinical Considerations when Switching. *International Clinical Psychopharmacology, 25*, 180-182.
- Mitchell, A. J. & Selmes, T. (2007). Why don't patients take their medicine? Reasons and solutions in psychiatry. *Advances in Psychiatry Treatment, 13*, 336-346.
- Pi, E. H. & Simpson, G. M. (2005). Cross-cultural psychopharmacology: A current clinical perspective. *Psychiatric Services, 56*, 31-33.
- Tood-Bazemore, B. (1999). Cultural issues in psychopharmacology: Integrating medication treatment with Lakota Sioux Traditions. *Journal of Clinical Psychology in Medical Settings, 6*, 139-150.
- Wong, F.K. & Pi, E.H. (2012). Ethnopsychopharmacology considerations for Asians and Asian Americans. *Asian Journal of Psychiatry, 5*, 18-23.

## **Psychopharmacology of Anxiety Disorders**

### **Week 6**

- History on the concept of anxiety
- Introduction of benzodiazapines
- Review of pharmacodynamics

#### **Read:**

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 6

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapters 9 and 18.

#### **Articles:**

Farach, F. J., Pruitt, L. D., Jun, J.J., Jerud, A. B., Zoellner, L.A., & Roy-Byrne, P.P. (2012). Pharmacological treatment of anxiety disorders: Current treatments and future directions. *Journal of Anxiety Disorders, 26*, 833-

843.

Perna, G., Alciati, A., Riva, A., Micieli, W., & Caldirola, D. (2016). Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. *Current Psychiatry Reports, 18*, 1-16.

Rivas-Vazquez, R. A. (2001). Antidepressants as first-line agents in the current pharmacotherapy of anxiety disorders. *Professional Psychology: Research and Practice, 32*, 101-104.

Rivas-Vazquez, R. A. (2003). Benzodiazepines in contemporary clinical practice. *Professional Psychology: Research and Practice, 34*, 324-328.

## **Psychopharmacology of Unipolar Depression and Bipolar Disorders**

### Week 7

- What is Depression?
- Discovery of Iproniazid
- Review of pharmacodynamics
- TCAs, MAOIs, SSRIs, and Heterocyclics
- Theories of anti-depressant chemical/biological action

### *Read:*

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 5 & 8

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapters 7, 8, 10,16-17.

### *Articles:*

Ankarberg, P. & Falkenstromm F. (2008). Treatment of Depression with Antidepressants is primarily a psychological treatment. *Psychotherapy Theory, Research, Practice, Training, 45*, 329-339.

Chang, T., & Fava, M. (2010). The future of psychopharmacology of depression. *The Journal of Clinical Psychiatry, 71*, 971-5.

Dharmshaktu, P., Tayal, V., & Kalra, B. S. (2011). Efficacy of Antidepressants as Analgesics: A Review. *The Journal of Clinical Pharmacology, 40*, 1-12.

Jimenez-Solem, E., Andersen, J., Petersen, M., Broedbaek, K., Lander, A., et al. (2013). SSRI use during pregnancy and risk of stillbirth and neonatal mortality. *American Journal of Psychiatry, 170*, 299-304.



## Psychopharmacology of Psychotic Disorders

### Week 8

- History of the concept of psychosis
- Comparison of Neuroleptics with 2nd generation antipsychotics
- Review of pharmacodynamics
- Role of Extra-pyramidal Symptoms
- Benefits of Atypical agents
- Suggested treatment protocol

#### Read:

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 7

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapters 11 & 19.

#### Articles:

Cerovecki, A., Musil, R., et al. (2013). *Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations*. *CNS Drugs*, 27, 545-572.

Cianchetti, C. & Ledda, M. G. (2011). *Effectiveness and safety of Antipsychotics in early onset psychoses: A long-term comparison*. *Psychiatry Research*, 189, 349-356.

Edlinger, Monika, Baumgartner, Susanne, Eltanaihi-Furtmüller, Nadja, Hummer, Martina, & Fleischhacker, W. (2005). *Switching Between Second Generation Antipsychotics*. *CNS Drugs*, 19, 27-42.

Holmes, J.S., Zacher, J.L. (2012). *Second-generation antipsychotics: A review of recently approved agents and drugs in the pipeline*. *Formulary Journal*, 47, 106-121.

Meyer, J. (2017). *Converting oral to long-acting injectable antipsychotics: A guide for the perplexed*. *CNS Spectrums*, 22, 17-27.

Muench, J., & Hamer, A. (2010). *Adverse effects of antipsychotic medications*. *American Family Physician*, 81, 617-22.

Park, T., Usher, K., & Foster, K. (2011). *Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics*. *International Journal of Mental Health Nursing*, 20, 428-437.

Rivas-Vazquez, R. A., Blais, M. A., Rey, G. J., & Rivas-Vazquez, A. A. (2000). Atypical antipsychotic medications. Psychopharmacological profiles and psychological implications. *Professional Psychology: Research and Practice, 31*, 628-640.

Rivas-Vazquez, R. A. & Rey, J. (2002). Weight gain and metabolic disturbances associated with the atypical antipsychotics. *Professional Psychology: Research and Practice, 33*, 341-344.

## **Medicating Children: Perspectives, Dilemmas, and Challenges**

Week 09

- Psychotropic medication for children and adolescents
- Review of pharmacodynamics (psychostimulants)
- Stimulant medication—Treatment of ADHD disorders of attention
- Mood stabilizers and Bipolar I with children
- Anti-depressant medication
- Anti-anxiety medication
- School issues and anxiety

### **Read:**

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 9

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapter 23.

### **Articles:**

Andersen, S. L., & Navalta, C.P. (2004). Altering the course of neurodevelopment: A framework for understanding the enduring effects of psychotropic drugs. *International Journal of Developmental Neuroscience: The Official Journal of the International Society for Developmental Neuroscience, 22*, 423-440.

Correll, C.U., Kratochvil, C.J., & March, J.S. (2011). Developments in pediatric psychopharmacology: Focus on stimulants, antidepressants, and antipsychotics. *The Journal of Clinical Psychiatry, 72*, 655-70.

Mcclellan, Jon, & Stock, Sandra. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *Journal of the American Academy of Child and Adolescent Psychiatry, 52*, 976-90.

- Nielsen, R., Laursen, M., Vernal, D., Bisgaard, C., Jakobsen, H., et al. (2014). Risk of diabetes in children and adolescents exposed to antipsychotics: A nationwide 12-year case-control study. *Journal of the American Academy of Child and Adolescent Psychiatry*, 53, 971-979.
- Olfson, Mark, King, Marissa, & Schoenbaum, Michael. (2015). Treatment of Young People with Antipsychotic Medications in the United States. *JAMA Psychiatry*, 72, 867-874.
- Southammakosane, C., & Schmitz, K. (2015). Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety. *Pediatrics*, 136, 351-359.
- Tran, Allen R, Zito, Julie M, Safer, Daniel J, & Hundley, Sarah D. (2012). National trends in pediatric use of anticonvulsants. *Psychiatric Services (Washington, D.C.)*, 63, 1095-1101.
- Zuddas, A., Zanni, R., & Ursula, T. (2011). Second Generation Antipsychotics (SGAs) for Non-Psychotic disorders in Children and Adolescents: A review of the randomized controlled studies. *European Neuropsychopharmacology*, 21, 600-620.
- Zuvekas, S., & Vitiello, B. (2012). Stimulant medication use in children: A 12-year perspective. *The American Journal of Psychiatry*, 169, 160-166.

## Midterm Examination

### Week 10 **Psychopharmacology of Personality Disorders and Other Related Disorders**

- Review of personality disorders
- Tailoring medication to symptom clusters
- Medical and psychiatric co-morbidity
- Chronic pain
- Eating disorders and obesity
- Impulse control disorders
- Red Flags: When to Reevaluate

#### Read:

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapters 13 & 15, 22.

#### Articles:

Ripoll, L., Triebwasser, J., & Siever, L. (2011). Evidence-based pharmacotherapy for personality disorders. *The International Journal of Neuropsychopharmacology*, 14, 1257-1288.

**Psychopharmacology of Chemical Dependency and Co-Occurring  
Week 11      Conditions**

- Neurobiology of Addictive Behavior
- Types of Addiction Medication Agents
- Dopamine Hypothesis
- Dual diagnosis
- Co-Occurring conditions
- Drug prescription for dual-diagnosis clients

*Read:*

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 11

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapter 14.

*Articles:*

Ershe, K.D. & Sahakian, B.J. (2007). The neuropsychology of amphetamine and opiate dependence: Implications for treatment. *Neuropsychology Rev*, 17, 317-336.

Hilton, D.L. & Watts, C. (2011). Pornography addiction: A neuroscience perspective. *Surgical Neurology International*, 2, 15-18.

Mo, Y., Thomas, M., & Karras, G. (2016). Barbiturates for the treatment of alcohol withdrawal syndrome: A systematic review of clinical trials. *Journal of Critical Care*, 32, 101-107.

Ray, L.A. (2012). Clinical neuroscience of addiction: Applications to psychological science and practice. *Clinical Psychology: Science and Practice*, 19, 154-166.

**Review of Case Studies**

Week 12      \*Integration of client history, DSM diagnosis, and psychotropic medication  
**NOTE: Interview Paper due**

**Role of Herbal Treatment, Vitamins, and Marijuana Use**

Week 13

- Weeds, seeds, and New Age needs
- Why take Herbaceuticals?

- Problems in studying medicinal plants
- History of Marijuana use
- Overview of Hallucinogens

*Read:*

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 10

Preston, J. O'Neil, J., & Talaga, M. C. (2017). *Handbook of Clinical Psychopharmacology for therapists*. Chapter 20.

*Articles:*

Dyck, E. (2005). Flashback: psychiatric experimentation with LSD in historical perspective. *Canadian Journal of Psychiatry*, 50, 381-388.

Firenzuoli, F., & Gori, L. (2007). Herbal medicine today: clinical and research issues. *Evidence-Based Complementary and Alternative Medicine*, 4(S1), 37-40.

Ingersoll, R. E. (2005). Herbaceuticals: An overview for counselors. *Journal of Counseling & Development*, 83, 434-443.

Rivas-Vazquez, R. A. (2001). St. John's Wort: Practical considerations based on the evidence. *Professional Psychology: Research and Practice*, 32, 329-332.

Rivas-Vazquez, R. A. & Delgado, L. (2002). Clinical and toxic effects of MDMA. *Professional Psychology: Research and Practice*, 33, 422-425.

Saki, K., Bahmani, M., & Rafieian-Kopaei, M. (2014). The effect of most important medicinal plants on two important psychiatric disorders (anxiety and depression)-a review. *Asian Pacific Journal of Tropical Medicine*, 7, S34-S42.

Sarris, J., Panossian, A., Schweitzer, I., Stough, C., & Scholey, A. (2011). Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. *European Neuropsychopharmacology*, 21(12), 841-860.

Shelley, B.M., Sussman, A.L., Williams, R.L., Segal, A.R., Crabtree, B.F. (2009). They Don't Ask Me So I Don't Tell Them: Patient-Clinician Communication about Traditional, Complementary, and Alternative Medicine. *Annals of Family Medicine*, 7, 139-147.

Weigl, D.J., Donovan, K.A. Krug, K.S., & Dixon, W.A. (2007). Prescription Opioid Abuse and Dependence: Assessment Strategies for Counselors. *Journal of Counseling & Development, 85*, 211-215.

## **Ethical Issues in Psychopharmacology Consultation**

Week 14

- Expected Standard of Care
- Co-occurring diagnostic conditions
- Current trends
- Professional practice guidelines
- Mental illness and freedom to refuse treatment
- Collaboration with prescribing professionals
- Recommended Ethical guidelines
- Use of Hallucinogens in healing process

### *Read:*

Ingersoll, E., & Rak, C. (2016). *Psychopharmacology for Mental Health Professionals: An Integrative Approach 2nd Edition*. Boston, MA: Cengage Learning. Chapter 12

Preston, J., O'Neal, J. H., & Talaga, M. C. (2017). *Handbook of clinical psychopharmacology for therapists*, Chapters 5, 21, 22.

### *Articles:*

Bassman, R. (2005). Mental illness and the freedom to refuse treatment. Privilege or right. *Professional Psychology: Research and Practice, 36*, 488-497.

Cassetta, B., & Goghari, V. (2014). Ethical Considerations of Screening and Early Intervention for Clinical High-Risk Psychosis. *Ethics & Behavior, 1*-20.

Jensen, P. S. (1998). Ethical and pragmatic issues in the use of psychotropic agents in young children. *Canadian Journal of Psychiatry, 43*, 585-588.

King, J. H. & Anderson, S. M. (2004). Therapeutic implications of pharmacotherapy: Current trends and ethical issues. *Journal of Counseling & Development, 82*, 329-336.

Oberleitner, L., Zumberg, K., Grekin, E., & Tzilos, G. (2011). Psychotropic drug use among college students: Patterns of use, misuse, and medical monitoring. *Journal of American College Health, 59*, 658-661.

Wiechers, I., Leslie, D., & Rosenheck, R. (2013). Prescribing of psychotropic medications to patients without a psychiatric diagnosis. *Psychiatric Services, 64*, 1243-1248.

Calendar is only an example and may be quite different 15

***Final Examination***  
Week 15